Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology (AAN) 2024
Seismic Therapeutic, Inc ., the machine learning immunology company, today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) 2024 annual meeting in Denver.
- Seismic Therapeutic, Inc ., the machine learning immunology company, today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) 2024 annual meeting in Denver.
- The poster presentation titled, “Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases,” features preclinical in vitro and in vivo results supporting the differentiated therapeutic profile of S-1117.
- S-1117 reduced IgG effector functions, significantly reducing antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of peripheral blood mononuclear cells (PBMCs).
- A murine nephritis model showed reduced complement and immune complex deposition, as well as reduced proteinuria, blood urea nitrogen and renal pathology.